Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

28 Jan 2021 07:00

RNS Number : 1233N
Biome Technologies PLC
28 January 2021
 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

28 January 2021

Biome Technologies plc

("Biome", "the Company" or "the Group")

Trading Update

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited pre-close trading update for the financial year ended 31 December 2020.

Group revenues for the year ended 31 December 2020 were broadly in line with market expectations at £5.7m (2019: £6.9m) following strong annual revenue growth of 65% in the Bioplastics division.

Cash balances at the year-end were £1.7m, following the net £1m equity fundraising announced in September 2020 (30 September 2020: £0.9m).

The Board anticipates that, subject to completion of the audit process, the Group will generate a loss before interest, taxation, depreciation, amortisation and share option charges for the year ended 31 December 2020, which will be in line with current market expectations.

The Group's preliminary results for the year ended 31 December 2020 are scheduled to be published on 25 March 2021.

Bioplastics Division

The division's revenues for the full year to 31 December 2020 were £4.9m, 65% ahead of full year 2019 revenues of £3.0m. Revenues in Q4 were £1.2m, 20% ahead of the prior year comparative quarter (Q4 2019: £1.0m), but lower than the preceding quarter (Q3 2020: £1.6m) as indicated in the Company's Trading Update on 29 October 2020.

The Board expects significant revenue growth from this division in 2021, with further product implementations in progress with both existing and new customers.

Stanelco RF Technologies Division

Revenues for the division for the full year to 31 December 2020 were £0.8m, £0.3m being generated in Q4, slightly ahead of the preceding quarter's revenue of £0.2m. This subdued revenue level reflects the on-going over-capacity in the division's main fibre-optic cable market.

The division has substantially reduced its overheads in the last year and is focussing on growing its presence in its other markets, resulting in a growing pipeline of opportunities. The Board is continuing to monitor the division's trading outlook carefully.

Group Performance

Throughout the Covid-19 pandemic, the Group has continued its manufacturing and development operations in conformance with Government advice, ensuring the safety of staff. The Group continues to make selective use of the UK Government's Job Retention Scheme for staff within the Stanelco RF Technologies division.

Whilst the Board anticipates the Group's loss before interest, taxation, depreciation, amortisation and share option charges for the year to be in line with current market expectations, the Statutory Underlying Loss is likely to be below market expectations due to a larger than anticipated non-cash share-based payment charge.

The Group's cash position as at 31 December 2020 was £1.7m (30 September 2020: £0.9m). In Q4, the cash position was increased by the equity fundraising announced in September 2020 of £1.0m (net of costs), to support the continuing growth of the Bioplastics division. The remainder of the change in the Group's cash position was a result of trading performance in the quarter. The Group has no debt.

Group Outlook

Whilst the longer-term outlook for the Stanelco RF Technologies division is slightly more encouraging than in 2020, the Board expects that headwinds will continue in the short term.

The underlying trends and technical innovation that have driven growth in the Bioplastics division are anticipated to continue as consumers increasingly demand that plastic waste is managed in a better manner. The projects that underpin the division's expected growth in 2021 are proceeding well.

The Board remains confident of meeting market expectations in 2021.

- Ends -

For further information please contact: Biome Technologies plc

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

info@biometechnologiesplc.co.uk

Tel: +44 (0) 2380 867 100

www.biometechnologiesplc.com

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656

www.allenbycapital.com

 

About Biome

 

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited.

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers.

 

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKOBPOBKDFDB
Date   Source Headline
29th Jan 20157:00 amRNSOperational Update
22nd Jan 20157:00 amRNSPre-close Trading Statement
21st Jan 20154:35 pmRNSHolding(s) in Company
11th Dec 201410:11 amRNSChange of Adviser
14th Nov 20149:58 amRNSHolding(s) in Company
4th Nov 20147:00 amRNSTrading Update
3rd Sep 20147:00 amRNSInterim Results
12th Aug 20149:36 amRNSHolding(s) in Company
31st Jul 20147:00 amRNSContract progress for RF Technologies Business
24th Jul 20143:28 pmRNSTrading Update
6th Jun 20143:56 pmRNSHolding(s) in Company
7th May 20147:00 amRNSEMI Share Option Plan
23rd Apr 201412:26 pmRNSResult of AGM and Appointment of Director
23rd Apr 20147:00 amRNSTrading Update
31st Mar 20147:00 amRNSUpdated Corporate Presentation
28th Mar 20147:02 amRNSPosting of Notice of AGM & Annual Report
27th Mar 20147:00 amRNSPreliminary Results
24th Mar 201411:43 amRNSContract for Stanelco RF Technologies Division
19th Feb 20149:01 amRNSHolding(s) in Company
24th Jan 20147:00 amRNSPre-close Trading Statement
4th Dec 20133:37 pmRNSIssue of Shares to Director
28th Nov 20131:30 pmRNSDirector/PDMR Shareholding
27th Nov 20137:00 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSTrading Update
31st Oct 201312:27 pmRNSTotal Voting Rights
2nd Oct 201312:47 pmRNSIssue of Shares to a Director
27th Sep 20138:51 amRNSTR-1: Notification of Major Interest in Shares
25th Sep 201312:33 pmRNSResult of General Meeting
2nd Sep 20137:10 amRNSNotice of General Meeting
2nd Sep 20137:00 amRNSInterim Results
26th Jul 20137:00 amRNSPurchase of Shares following Consolidation
18th Jul 20137:00 amRNSInterim Management Statement
20th Jun 20132:34 pmRNSIssue of Equity
20th Jun 201312:45 pmRNSResult of General Meeting
17th Jun 201312:01 pmRNSHolding(s) in Company
17th Jun 201311:59 amRNSHolding(s) in Company
23rd May 20137:01 amRNSCapital Reorganisation
23rd May 20137:00 amRNSSettlement with Landlord in Respect of Leases
26th Apr 20137:00 amRNSIssue of shares to a Director Total Voting rights
25th Apr 20134:10 pmRNSResult of AGM
25th Apr 20137:00 amRNSTrading Update
4th Apr 20137:00 amRNSResearch Grant Award
3rd Apr 20134:35 pmRNSNotice of AGM and Annual Report and Accounts
28th Mar 20137:10 amRNSDirector's Remuneration and Consultancy agreement
28th Mar 20137:01 amRNSPreliminary Results
23rd Jan 20137:00 amRNSPre-close Trading Statement
2nd Nov 20127:00 amRNSTrading Update
1st Oct 20123:24 pmRNSCompletion of Sale
27th Sep 20122:03 pmRNSResult of General Meeting
7th Sep 20127:00 amRNSProposed Sale of stake in Biotec Holding GmbH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.